Litcius/Paper detail

Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review

Alina Dima, Madelon C Vonk, Alexandru Garaiman, BE Kersten, R Becvar, Michal Tomčík, A. M. Hoffmann-Vold, I. Castellví, JL Tandaipan Jaime, Marek Brzosko, Marcin Milchert, Dorota Krasowska, Małgorzata Michalska‐Jakubus, Paolo Airó, Marco Matucci‐Cerinic, Cosimo Bruni, Michele Iudici, JHW Distler, AM Gheorghiu, Hadi Poormoghim, Francesca Motta, Maria De Santis, M. Pârvu, Oliver Distler, Carina Mihai

2024European Journal of Internal Medicine14 citationsDOIOpen Access PDF

Topics & Concepts

MedicineScleroderma (fungus)Internal medicineCohortAnti-nuclear antibodyClinical significanceCohort studyDermatologyAntibodyAutoantibodyPathologyImmunologyInoculationSystemic Sclerosis and Related DiseasesMultiple Sclerosis Research StudiesInflammatory Myopathies and Dermatomyositis
Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review | Litcius